Renal Cancer also known as Renal cell adenocarcinoma (RCC) or Kidney cancer are a group of cancers that start from the kidneys. Symptoms of renal cancer can include lumps in the abdomen, blood in the urine, or chronic back pain. Other symptoms can include rapid weight loss, fever. Kidney cancer is diagnosed with oncologists find abnormal growth of cells in the kidney tissue. Over time, these cells form a tissue mass known as a tumor.
Kidney cancer can begin when something in the environment triggers a change in renal cells causing them to divide uncontrollably. If a malignant or cancerous tumor can spreads to other tissues or vital organs it’s called metastasis. Kidney cancer can metastasize to several organs including the liver, lungs or brain.
Based on recent statistics from 2021, Renal cancer is the ninth most commonly occurring cancer in men and the fourteenth-most common cancer type in women. The total number of patients with renal cell adenocarcinoma cancer has nearly tripled since the 1980s. There is an increasing global trend for the incidence of kidney cancer globally, particularly in younger populations and european countries. Doctors have identified several modifiable risk factors for developing kidney cancer. The rapicly increasing incidence of kidney cancer amongst young individuals is quite worrying and requires early intervention with active preventive measures.[1]
Those most susceptible to developing kidney cancer include: People between the ages of 65 and 74 have the highest incidence of developing kidney cancer, and the prevalence of the condition in men is two times that in women. Additionally, Native Americans and people of African descent are disproportionately affected. In contrast to adults, children seldom get kidney cancer. However, every year, between 5000 and 6000 children are diagnosed with Wilms tumours, a rare kind of kidney cancer.
There are many kidney cancer variations and each type is quite different in the way it develops and mutates over time. Treatment options also vary depending on the type, scale, and severity of the diagnosis. The three most common types of renal cancer include:
RCC is the most common form of kidney cancer in the world. RCC is responsible for 85% of all kidney malignancies and is the most frequent kind of kidney cancer in adults. While renal cell carcinoma most often manifests as a solitary tumor in just one kidney, it can also spread to the other organs and often seen in patients with chronic liver disease and alcoholic liver cirrhosis. Cancer develops in the tubular epithelium that lines your kidneys (tiny tubes that return nutrients and fluid to your blood). Clear-cell renal cell carcinoma (RCC) accounts for most cases (ccRCC).
Six to seven per cent of all kidney malignancies are transitional cell carcinomas. Uterine carcinoma typically develops at the point where the ureter branches off from the kidney proper. Your renal pelvis is the place where your kidneys are located. The ureters and bladder are potentially potential sites of progression for transitional cell cancer. [2]
Renal sarcoma is extremely rare, making up about 1% of all instances of kidney cancer. The kidneys are the site of origin for this disease, which can spread to other organs and bones if left untreated. Renal sarcoma forms in oft tissue, the connective tissue surrounding the kidneys or the adipose fat around the kidneys. Less than 1 percent of identified kidney cancers are classified as renal sarcoma.
Wilms tumour is commonly a type of renal cancer in children. Wilms’ tumor is also known as nephroblastoma, and most often affects children from the ages 3 to 5 but becomes much less previlent after the age of 5.
About 9.7% of all malignancies are diagnosed as kidney cancer. On average, around 566,000 people are diagnosed with kidney cancer each year, and renal cancer is more likely to be diagnosed in older people. In its early stages, kidney cancer may not cause any symptoms. Yet, signs and symptoms may emerge as the tumor develops. This is why kidney cancer is frequently not identified until it has already spread to other organs.
Sometimes, the tumors found in the Kidneys are classified as noncancerous (benign). This type of cancer usually doesn’t cause any severe symptoms or discomfort. Benign renal tumors are often found by chance when a patient undergoes imaging tests for other health conditions. Common benign tumors in the kidneys include:
An important part of dealing with kidney cancer is by first classifying it into one of fours stages it is currently in. This helps with planning for the appropriate treatment based on stage and severity. The stage of renal cancer will be based on several factors including staging & diagnostic to accurately determine which stage kidney cancer is in.
There are essentially four basic stages:
Lymph nodes are like little “filters,” collecting and storing white blood cells that may be used to fend against infections. To measure the level of dysfunction in am patients lymph nodes and to measure the size of tumors, a doctor utilizes radiology scans such as CT and MRI, along with biological samples (via biopsy) from tumours, to establish the extent of the disease.
Grades are assigned to tumours to reflect the degree to which their cells deviate from normality. The rate of tumour growth can also be estimated by grading. High-grade tumors are characterized by rapidly dividing abnormal cells that don’t resemble healthy tissue. It is common for high-grade tumors to develop and spread faster than low-grade ones.
To reach a diagnosis, an oncologist looks thorough a patients medical history records and do a preliminary physical examination looking for signs of kidney cancer. They may also request tests that aid in detecting and evaluating cancer. Indicators that may be used in such examinations are:
Major risk factors associated with cancer in the kidneys include:
Having any of some of these risk factors does not mean you will automatically get kidney cancer. It’s also possible that patients can have none of these symptoms but still get the disease.[4]
When a patient is diagnosed with kidney cancer, oncologists will first try to determine if the cancer tumors have spread, and if so, how far. Oncologists can then use the patient’s cancer stage and current health to discuss best treatment options that offer the highest survival chances.
Surgery is still considered the first option for treatment for benign kidney tumors or non-metastasized kidney cancer. Laparoscopic surgeries offer a minimally invasive surgery and only needs small incisions in the patients abdomen. Doctors can then insert a small camera and other medical instruments to target and destroy the tumor. Recent clinical trials have shown that laparoscopic surgery is equally effective as previous surgery but allows for a much easier recovery.
For some patients, doctors carefully monitor the tumor for abnormal growth over time. This process is known as “watchful waiting.” Or “active surveillance”. The final decision to pursue a treatment action after active surveillance will depend on several factors, including:
Biologic based therapies such as NK Cell Therapy also known as Immunotherapy, are a new type of kidney cancer treatment that is designed to increase our body’s own defense mechanisms to fight cancer. mRNA technology and Biologic therapies can use autologous materials (made by the patients body) or allogenic materials (cultured inside laboratory) to target, restore and boost the immune systems function. It can be used to:
Most patients diagnosed with Renal cell carcinoma (RCC) are treated with combinations of radiation therapy, chemotherapy, or surgery. Radiation based therapies are disadvantageous as the high-energy particle rays do not target the cancer cells and destroy healthy cells causing severe side effects. The levels of radiation exposure in chemotherapeutic doses must be limited to avoid organ toxicity. Therefore, the 21st Century approach requires more precisely targeted therapies that are capable of killing cancer cells while ignoring the healthy cells.
The combination of modern immunological cancer therapies and MSC+ stem cells uses a more holistic approach and is significantly less toxic while maintaining similar and often better results depending on the type, age, and diagnosis stage. Immune boosting therapies are also more effective in achieving long-term tumor immunosurveillance while reducing the chance of relapse.
Immunological therapies for kidney cancer can increase long-term disease-free survival and are prescribed as adjuvant therapy for patients with low white blood cell counts. Stem cell therapy for renal cancer helps boost a patient immune system with a naturally produced growth factor to enhance the cancer-fighting capacity.[5]
Immunotherapy for kidney cancer is quickly becoming a viable standard-of-care treatment and, in some cases, a complete cure. Immunotherapies refers to manipulating or mobilizing the patient’s immune system to treat or cure kidney cancer. Immunological therapies can also be performed via manipulation of genes using Dendritic cells (DCs), Immune modulators, monoclonal antibodies therapy, adoptive cell transfer and the new oncolytic virus therapy, which is a virus-based delivery system of modified genes where the payload uses the viruses as a host to carry past the patient’s immune system.
Patients who are diagnosed with stage 3 kidney cancer who initially might have responded well to medications that target PD-1 protein (checkpoint inhibitors) can, over a short time, develop resistance to these therapies, significantly if cancer has metastasized from its primary location to spawn additional kidney lesion and tumors. In such cases, CAR T Cells & genes encoded with tumor-associated antigens (TAA) induces a much for an adequate response from the immune system.
Earlier clinical trials on late stage kidney cancer focused on identifying the proliferating progenitor cells (CD34+) in human blood. These progenitor cells are stimulated by cytokines (GM-CSF and TNF-alpha) to differentiate into dendritic cells rapidly. For some cases, using a combination of IL-4 & GM-CSF helps to generate significantly larger quantities of cancer-fighting dendritic cells from monocytes and macrophages.
Immunological therapy for kidney cancer might soon be the gold standard in the treatment of renal tumors for these reasons:
The Regeneration Center offers an alternative treatment for kidney cancer that can treat or reverse symptoms depending on the patient’s stage. The best defense from any cancer is first being informed about the disease to make an informed decision about biological treatment for cancer using stem cells.
Our stem cell therapy for kidney cancer is customized specific to patient needs. The individualized protocol helps patients fight cancer using traditional cancer treatment and alternative natural cellular-based therapies. For over 15 years, our approach to integrated healthcare relies on research-based treatment plans comprehensive and specific to patient medical needs to ensure the highest chances of success. The Regeneration Center offer a holistic approach to modern healthcare. We strive to fight cancer and alleviate underlying symptoms that can increase the patient’s quality of life. Cancer stem cell treatment plans also helps patients achieve long term remission rates by addressing the root cause of disease and not just its symptoms.
Some herbal based treatment might help treat some symptoms associated with kidney cancer, however patients diagnosed with cancer need to be extra precautious before digesting an herbal remedy of unknown sources. A compromised renal system may have a much harder time metabolizing substances. Since many herbal preparations and extracts are alcohol-based, kidney cancer patients should always double-check all the ingredients before taking any herbs. Furthermore, some herbal supplements for kidney cancer can cause excessive bleeding and prevent blood from clotting properly.
Primary kidney cancer can be defeated. Our goal is to heal the body from the inside out and help patients achieve the longest possible rates of remission. Our natural cell based approach to healthcare means that we will work with you and your primary care doctor to determine the best overall treatment options. Our treatment evaluation for kidney cancer does require review of current medical records. Patients who for some reason are not responding to traditional treatments or those where surgery is not a good option, our team can review your Radiology scans (CT, ultrasound, or MRI) and lab tests to target the tumor(s) better and destroy them using minimally invasive techniques. We provide you with access to innovative kidney cancer treatment techniques and immunotherapies when appropriate. The Regeneration Center also offers its patients comprehensive follow-up care and survivorship programs ( In Thailand only) for patients recovering from kidney cancer.
The outlook for patients diagnosed with renal cancer has never been better. Thanks to modern medicine, many people survive the disease. The Regeneration Cancer center has cared for patients worldwide who were diagnosed with different types of kidney lesions and stages of kidney cancer. To learn more about our treatment protocols and biological therapy for kidney cancer please contact us today.
[1] ^ Linehan WM, Schmidt LS, Crooks DR, Wei D, Srinivasan R, Lang M, Ricketts CJ. The Metabolic Basis of Kidney Cancer. Cancer Discov. 2019 Aug;9(8):1006-1021. doi: 10.1158/2159-8290.CD-18-1354. Epub 2019 May 14. PMID: 31088840.
[2] ^ Turajlic S, Swanton C, Boshoff C. Kidney cancer: The next decade. J Exp Med. 2018 Oct 1;215(10):2477-2479. doi: 10.1084/jem.20181617. Epub 2018 Sep 14. PMID: 30217855; PMCID: PMC6170181
[3] ^Dziedzic K, Pleniceanu O, Dekel B. Kidney stem cells in development, regeneration and cancer. Semin Cell Dev Biol. 2014 Dec;36:57-65. doi: 10.1016/j.semcdb.2014.08.003. Epub 2014 Aug 13. PMID: 25128731.
[4] ^Bi LK, Zhou N, Liu C, Lu FD, Lin TX, Xuan XJ, Jiang C, Han JL, Huang H, Zhang CX, Dong W, Liu H, Huang J, Xu KW. Kidney cancer cells secrete IL-8 to activate Akt and promote migration of mesenchymal stem cells. Urol Oncol. 2014 Jul;32(5):607-12. doi: 10.1016/j.urolonc.2013.10.018. Epub 2014 Jan 10. PMID: 24412633.
[5] ^ Fang P, Zhou L, Lim LY, Fu H, Yuan ZX, Lin J. Targeting Strategies for Renal Cancer Stem Cell Therapy. Curr Pharm Des. 2020;26(17):1964-1978. doi: 10.2174/1381612826666200318153106. PMID: 32188377